E7090
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced or Recurrent Solid Tumors
Conditions
Advanced or Recurrent Solid Tumors, FGFR Gene Alterations
Trial Timeline
Jun 15, 2021 → Mar 31, 2028
NCT ID
NCT04962867About E7090
E7090 is a phase 2 stage product being developed by Eisai for Advanced or Recurrent Solid Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04962867. Target conditions include Advanced or Recurrent Solid Tumors, FGFR Gene Alterations.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04962867 | Phase 2 | Recruiting |
| NCT04238715 | Phase 2 | Completed |
| NCT02275910 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced or Recurrent Solid Tumors